<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01177163</url>
  </required_header>
  <id_info>
    <org_study_id>CR014881</org_study_id>
    <nct_id>NCT01177163</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Type-2 Diabetes Mellitus Subjects Not Optimally Controlled (A1C &gt;=7.0%) on Fixed Doses of Insulin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacodynamic effects
      and pharmacokinetic characteristics of JNJ-28431754 after multiple dosing in patients with
      Type 2 Diabetes Mellitus who are on a stable dose of insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (study drug assigned by chance), double-blind (neither the patient or
      the study doctor will know the name of the assigned treatment), parallel-group (each group of
      patients will be treated at the same time) to determine the safety, tolerability,
      pharmacokinetics (PK) (how drugs are absorbed in the body, how they are distributed within
      the body and how they are removed from the body over time) and the pharmacodynamics (PD) (the
      action or effects a drug has on the body) of oral (taken by mouth) doses of JNJ 28431754
      taken once or twice daily compared to placebo (treatment identical in appearance to
      JNJ-2843174 but contains no active drug) in patients with Type 2 Diabetes Mellitus (T2DM) who
      are receiving therapy with a fixed-dose regimen of insulin. Two groups of 14 patients will be
      studied; one group will receive JNJ-2843174 (100 mg) or placebo once daily for 4 weeks and
      the other group will receive JNJ-2843174 (300 mg) or placebo twice daily for 4 weeks. In the
      3 days immediately prior to the beginning of the 4-week treatment period, all patients will
      take a single oral dose of placebo once daily and have blood and urine samples collected for
      laboratory testing. During the study, all patients will be allowed to continue on their
      normal medication regimen of insulin and other allowed anti-diabetic medications. On selected
      days during the study, patients will be required to stay overnight at the study center to
      have study drug administered and/or to have blood and urine samples collected for laboratory
      testing. During the study, if patients experience worsened glycemia (blood sugar), rescue
      therapy with additional insulin of the same type but at a higher dose may be initiated by the
      Investigator if medically appropriate. During the study, patients will be monitored for
      safety by review of adverse events and results from laboratory tests, 12-lead
      electrocardiograms (ECGs), vital signs measurements, body weight, physical examinations, and
      self-monitored blood glucose (SMGB) measurements. Unless otherwise specified, study drug will
      be taken orally (by mouth) after an overnight fast for at least 8 hours followed by a meal
      within 10 minutes; for twice daily dosing, the evening dose will be taken just prior to the
      evening meal (dinner). All patients will take one placebo capsule once daily for 3 days
      immediately prior to randomization. After randomization, patients will take JNJ-28431754 (100
      mg) or placebo once daily or JNJ-28431754 (300 mg) or placebo twice daily for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients who need to decrease insulin dosage from prestudy dosage levels because of hypoglycemia</measure>
    <time_frame>From time of signed informed consent (Days -52 to -32) through to the end of the study (Days 34 to 39) or at the time of early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with specific treatment-emergent adverse events</measure>
    <time_frame>From time of signed informed consent (Days -52 to -32) through to the end of the study (Days 34 to 39) or at the time of early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with symptomatic hypoglycemia and severe hypoglycemia</measure>
    <time_frame>From time of signed informed consent (Days -52 to -32) through to the end of the study (Days 34 to 39) or at the time of early withdrawal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations and pharmacokinetics parameters for JNJ 28431754</measure>
    <time_frame>At protocol-specified timepoints from Day 1 (pre-dose) to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose concentration-time profiles (pharmacodynamics parameter)</measure>
    <time_frame>At protocol specified timepoints on Day -1, Day 1, and Day 27</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urine glucose excretion (pharmacodynamics parameter)</measure>
    <time_frame>At protocol specified timepoints on Day -1, Day 1, and Day 27</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>001</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ 28431754 100 mg/placebo one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JNJ 28431754 300 mg/placebo one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo</description>
    <arm_group_label>001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ 28431754 300 mg/placebo</intervention_name>
    <description>one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks</description>
    <arm_group_label>003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ 28431754 100 mg/placebo</intervention_name>
    <description>one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks</description>
    <arm_group_label>002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have been diagnosed with T2DM for at least 6 months prior to study screening

          -  Be on stable insulin regimens at the time of screening

          -  Have a stable weight (ie, no change more than 5% in the 3 months prior to screening)

          -  Have a glycosylated hemoglobin (A1C) of &gt;=7% and &lt;=10.5% at study screening

        Exclusion Criteria:

          -  Have history of Type 1 diabetes mellitus, secondary forms of diabetes, diabetic
             ketoacidosis, pancreas or beta cell transplantation

          -  Have a known history of more than 2 severe hypoglycemic episodes as defined by the
             protocol within the past year

          -  Have history of, or currently active, significant illness as determined by the
             Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L. C. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&amp;studyid=787&amp;filename=CR014881_CSR.pdf</url>
    <description>A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in T2DM Subjects not Optimally Controlled (HbA1c: â‰¥7.0%) on Fixed Doses of Insulin Therapy</description>
  </link>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>May 27, 2013</last_update_submitted>
  <last_update_submitted_qc>May 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Canagliflozin</keyword>
  <keyword>JNJ-28431754</keyword>
  <keyword>Insulin</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>SGLT-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

